Your browser doesn't support javascript.
loading
The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study.
Ramchandren, Radhakrishnan; Johnson, Peter; Ghosh, Nilanjan; Ruan, Jia; Ardeshna, Kirit M; Johnson, Roderick; Verhoef, Gregor; Cunningham, David; de Vos, Sven; Kassam, Shireen; Fayad, Luis; Radford, John; Bailly, Sarah; Offner, Fritz; Morgan, David; Munoz, Javier; Ping, Jerry; Szafer-Glusman, Edith; Eckert, Karl; Neuenburg, Jutta K; Goy, Andre.
Afiliação
  • Ramchandren R; Division of Hematology/Oncology, University of Tennessee Health Science Center, Knoxville, TN, USA.
  • Johnson P; Cancer Research UK Clinical Centre, Southampton General Hospital, Southampton, UK.
  • Ghosh N; Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
  • Ruan J; Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.
  • Ardeshna KM; University College London/UCL Hospitals, Biomedical Research Centre, London, UK.
  • Johnson R; Leeds Cancer Centre at St. James's University Hospital, Leeds, UK.
  • Verhoef G; Department of Haematology, UZ Leuven - Campus Gasthuisberg, Leuven, Belgium.
  • Cunningham D; Gastrointestinal and Lymphoma Unit, The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital, London, UK.
  • de Vos S; Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Kassam S; Haematology Department, King's College Hospital, London, UK.
  • Fayad L; Department of Lymphoma-Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Radford J; Division of Cancer Sciences, The University of Manchester and the Christie NHS Foundation Trust, Manchester, UK.
  • Bailly S; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain Brussels, Brussels, Belgium.
  • Offner F; Department of Clinical Hematology, Universitair Ziekenhuis Gent, Ghent, Belgium.
  • Morgan D; Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
  • Munoz J; Department of Hematology, Banner MD Anderson Cancer Center, Gilbert, AZ, USA.
  • Ping J; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA.
  • Szafer-Glusman E; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA.
  • Eckert K; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA.
  • Neuenburg JK; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA.
  • Goy A; Department of Hematology & Oncology, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA.
EClinicalMedicine ; 56: 101779, 2023 Feb.
Article em En | MEDLINE | ID: mdl-36618900
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2023 Tipo de documento: Article